Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as a perioperative therapy for ...
The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the ...
“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of ...
Researchers have found in a Finnish population-based cohort study that diabetes and poor glycemic status were associated with ...
17hon MSN
Pfizer, Astellas post late-stage trial win for Padcev in bladder cancer with Merck’s Keytruda
Pfizer (PFE) stock is in focus as the firm with Astellas (ALPMF) post a Phase 3 trial win for Padcev cancer drug when used ...
A combination of the antibody-drug conjugate enfortumab vedotin (Padcev) and the PD-1 inhibitor pembrolizumab (Keytruda) ...
Merck (MRK) just cleared an important clinical hurdle, reporting strong Phase 3 KEYNOTE B15 results showing that KEYTRUDA ...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced positive topline results from an interim analysis of the Phase 3 EV-304 ...
Merck says Keytruda plus Padcev improved survival and response rates versus chemotherapy in a Phase 3 muscle-invasive bladder ...
Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its bladder cancer med is still one to watch as it competes with heavy hitt | ...
Merck, Pfizer and Astellas, which in August reported similar results from a Phase 3 study of the combination in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results